clinical trial · NCT05006794
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
Gilead Sciences·phase1·active not recruiting·n = 145
Solid MalignancieszamzetoclaxDocetaxelsacituzumab govitecan-hziy
brief summary
This is a Phase I open-label, multi-center study of zamzetoclax (formerly GS-9716) tested either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies. Primary objectives are to define the maximum tolerated dose (MTD) or maximum administered dose of zamzetoclax, and characterize the safety and tolerability of zamzetoclax as monotherapy and in combination with anti-cancer therapies.
started
Sep 15, 2021
primary completion
Mar 1, 2029
completion
Mar 1, 2029
last updated
Jan 7, 2026
official title
A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol